Updated interim results from COU-AA-302 support the expanded approval of abiraterone acetate in December 2012 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy.
Dr. Christopher P. Evans examines how autophagy, a relatively recently appreciated mechanism in cell and tumor biology, can regulate responses to prostate cancer treatments including chemotherapy and anti-androgen therapy in castrate-resistant prostate cancer.
Researchers at the 2013 Genitourinary Cancers Symposium presented the results of two negative phase III studies—READY and VENICE—of targeted agents that failed to increase overall survival when combined with standard first-line chemotherapy docetaxel/prednisone for the treatment of men with metastatic castration-resistant prostate cancer.The two agents are aflibercept and dasatinib.
Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to the survival analysis using data from the Social Security Death Index to assess any evidence of an increased risk of death in men randomized to finasteride, a potential indicator of a “true” increased risk of high-grade disease.
Compared with never smokers, current smokers had a reduced risk of prostate cancer which was statistically significant for localised and low-grade disease, but not for advanced or high-grade disease. In contrast, heavy smokers (25+ cigarettes per day) and men who had smoked for a long time (40+ years) had a higher risk of prostate cancer death.
SPRED2 is downregulated, especially in higher grade prostate tumors. These data suggest the first evidence that SPRED2 is downregulated in prostate cancer. Authors suggest these results warrant further studies of SPRED2 as a potential tumour-suppressor gene.
Study of 1000 older men that aimed to determine men’s preferences for prostate cancer screening, and to elicit the trade-offs they make found men were willing to trade-off 2.0% or 1.8% risk reduction of prostate ancer-related death to decrease their risk of unnecessary treatment or biopsy with 10%, respectively.
In a study of 129 healthy older men, cycling caused an average 9.5% increase in total PSA, in healthy male cyclists ≥50 years old, when measured within 5 minutes post cycling. The increase was considered clinically significant as the number of participants with an elevated PSA, according to established cut-offs, increased post-ride. Based on the research published to date, the authors suggest a 24–48 hour period of abstinence from cycling and ejaculation before a PSA test, to avoid spurious results.